Brain Metastases
Cross-source consensus on Brain Metastases from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Comparisons
Evidence quality
Highlighted claims
- SECOMBIT was the only included trial reporting brain metastases-related outcomes, so these data were not pooled. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Brain metastases-free survival did not significantly favour either treatment arm. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Survival after brain metastases detection after randomisation was not statistically significant between arms. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- New brain metastases were numerically less frequent in the ICI arm than in the targeted therapy arm. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials